Chronic Myeloid Leukaemia Europe

Chronic Myeloid Leukaemia Europe

Pharmaceutical Manufacturing

About us

Chronic Myeloid Leukaemia Europe informs European healthcare professionals around Incyte’s commitment to the treatment of patients with chronic myeloid leukaemia (CML). CML is one of the most common forms of leukaemia in adults and is divided into 3 stages: chronic phase, accelerated phase and blast phase.* View our social guidelines here: http://bit.ly/2sV0H5W *Rinaldi I. Winston K. J Blood Med. 2023;14:261–77.

Industry
Pharmaceutical Manufacturing
Company size
1,001-5,000 employees

Affiliated pages

Similar pages